Analytical Data
-
Gene name
DNASE1
- Application
-
Alternative Names
DNASE1；DNL1；DRNI；Deoxyribonuclease-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P24855
-
Expression Region
19-259aa
-
AA Sequence
GA VSLKIAAFNI QTFGETKMSN ATLVSYIVQI LSRYDIALVQ EVRDSHLTAV GKLLDNLNQD APDTYHYVVS EPLGRNSYKE RYLFVYRPDQ VSAVDSYYYD DGCEPCGNDT FNREPAIVRF FSRFTEVREF AIVPLHAAPG DAVAEIDALY DVYLDVQEKW GLEDVMLMGD FNAGCSYVRP SQWSSIRLWT SPTFQWLIPD SADTTATPTH CAYDRIVVAG MLLRGAVVPD SALPFNFQA
-
Molecular Weight
31 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DNASE1, or deoxyribonuclease I, is an enzyme that plays a crucial role in the degradation of extracellular DNA, primarily in the context of apoptosis and inflammation. Its primary function is to cleave DNA into smaller fragments, thus facilitating the removal of cellular debris and preventing potential autoimmune responses. Research on recombinant DNASE1 has gained significance due to its therapeutic potential in various diseases, particularly in conditions characterized by excessive DNA accumulation, such as cystic fibrosis. In cystic fibrosis patients, the accumulation of extracellular DNA from dead cells contributes to the thick mucus that obstructs airways, leading to chronic infection and inflammation. Recombinant DNASE1, such as the product Pulmozyme, has been developed to alleviate these symptoms by breaking down the viscous DNA, improving lung function and reducing infection rates. Furthermore, ongoing studies investigate the enzyme's applications in treating other pathologies, such as sepsis and certain types of cancer, where the regulation of extracellular DNA is crucial. The production of recombinant DNASE1 using modern biotechnological methods has allowed for increased yield and purity, enhancing its clinical efficacy. Research continues to explore the molecular mechanisms underlying DNASE1's activity and its interactions within the immune system, providing insights into novel therapeutic strategies for a range of inflammatory and autoimmune disorders. As our understanding of DNASE1 expands, it holds promise not only as a therapeutic agent but also as a tool for elucidating fundamental biological processes related to DNA metabolism and clearance.
